UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest even	nt reported)	November 18, 2015	
PI	VOT PHARM	ACEUTICALS INC.	
(Exact n	ame of registra	nt as specified in its chart	ter)
British Columbia	333-161157		n/a
(State or other jurisdiction of	(Commissio	on File Number)	(IRS Employer
incorporation)	× ·		Identification No.)
1275 West 6 th Avenue, Vancouver, British Columbia, Canada			V6H 1A6
(Address of principal executive offices)		(Zip Code)	
Registrant's telephone number, inclu	iding area code	(604) 805-77	783
		n/a	

n/a

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Appointment of Certain Officers and Directors; Departure of Certain Officers and Directors

On November 16, 2015, we accepted the resignation of Dr. BJ Bormann as director. We also accepted the resignation of Dr. Bormann as our Chief Executive Officer effective October 16, 2015. Dr. Bormann's resignation was not the result of any disagreements with our company regarding our operations, policies, practices or otherwise.

Dr. Ahmad Doroudian, our director and Chairman of the Board, has been appointed as our interim Chief Executive Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIVOT PHARMACEUTICALS INC.

Ahmad Doroudian Chairman

Date: November 18, 2015